Navigation Links
Ohr Pharmaceutical Appoints Thomas M. Riedhammer To Board Of Directors
Date:5/2/2013

NEW YORK, May 2, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of Thomas M. Riedhammer , Ph.D., to its Board of Directors. Dr. Riedhammer has over 35 years of ophthalmic industry experience, working for large and small pharmaceutical companies engaged in drug development through commercialization.

"We are pleased to have brought on someone of Dr. Riedhammer's caliber," stated Dr. Irach Taraporewala, CEO of Ohr. "Tom's proven expertise in building successful companies in the ophthalmic pharmaceutical industry will be an immeasurable asset to Ohr at this important juncture in the company's growth."

"I am excited to join the team at Ohr Pharmaceutical," commented Dr. Riedhammer. "Squalamine eye drops are a unique and potentially transformative product for wet-AMD patients, a large patient population currently being treated with chronic intravitreal injections directly into the eye. I look forward to contributing to the future growth of Ohr and providing benefit for patients in need."

Ira Greenstein , Chairman of the Board of Directors, added, "With our recent financing providing us with sufficient capital until 2015, anticipated enrollment milestones and a potential listing on Nasdaq on the horizon, it is a great time to welcome Dr. Riedhammer, with his wealth of experience in the development of ophthalmic companies, onto the team at Ohr."

Dr. Riedhammer has over 35 years of ophthalmic industry expertise.  Most recently, Dr. Riedhammer was Chairman of Sirion Therapeutics, where he was instrumental in raising over $100 million dollars of private equity and the subsequent FDA approval and launch of two ophthalmic products in the U.S. Prior to Sirion, Dr. Riedhammer served as the Chief Operating Officer
'/>"/>

SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ISPE End-to-End Supply Chain Conference - Stepping up Pharmaceutical Operations
2. Sterilization Market (Medical Devices, Pharmaceutical, Healthcare, Food Applications), Equipments & Contract Services - Global Forecast To 2017
3. White Mountain Process Announces Sanitary Autoclave Style Pharmaceutical Agitator
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Ohr Pharmaceutical Announces $5 Million Financing from Exercise of Warrants
8. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
9. Shimadzu's New DSC-60 Plus Series Differential Scanning Calorimeters Offer High-Sensitivity Analysis in Polymer, Food and Pharmaceutical Applications
10. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
11. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... /CNW/ - MaRS and Virgin Unite Canada, the non-profit foundation ... forces to support Canadian entrepreneurs tackling social and environmental challenges. ... at the MaRS Centre to announce the new partnership, which ... This fund has $1 million in seed capital provided by ... Mindset Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... July 7 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... executive officer (CEO), has announced his,intent to retire on ... to serve on the Board. Mr. Freiman is the ... California., Mr. Freiman is retiring after 11 years ...
... Pharmaceuticals,Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), ... announced the commencement,of a cash tender offer of ... amount that will result in an aggregate purchase ... Tender Premiums" listed in the,table below) of $165 ...
... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
Cached Biology Technology:Neurobiological Technologies' CEO to Retire on December 31, 2008 2Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 6Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 7Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 8Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... oceanographers including a researcher from Scripps Institution of Oceanography ... of tropical oceans are expanding as the oceans warm, ... marine organisms can live or enter in search of ... Stramma from the Leibniz Institute of Marine Sciences (IFM-GEOMAR) ...
... potential of biochar, or charcoal made from biological tissues (e.g., ... in the soil. This is because charcoal is carbon-rich and ... years. This has led to the suggestion being seriously considered ... large quantities and stored in soils. This would in turn ...
... University of Florida researchers have identified a drug ... and in a remarkable finding prevents damage ... hypertension. The findings, which appear in todays (May ... could lead to a new class of antihypertensive drugs ...
Cached Biology News:Oxygen depletion: A new form of ocean habitat loss 2Limitations of charcoal as an effective carbon sink 2UF scientists discover compound that could lead to new blood pressure drugs 2UF scientists discover compound that could lead to new blood pressure drugs 3
... for western blots ,• Optically clear plastic ... staining western blots. The reduced size (60 ... disposable tray requires less dye and antibodies ... the user. Pour spouts in each corner ...
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Qentix Western Blot Signal Enhancer does for enzyme-/substrate-based ... it increases the signal up to 10-fold ... minutes., ,The Western Blot Signal Enhancer membrane ... be added to your current Western blotting ...
... Solid phase extraction through columns is ... range of applications. Typical applications are in ... in diagnostics, or compound purification in chemical ... fully automated on the Genesis series instruments ...
Biology Products: